CA2069162A1 - Use of nizatidine to treat reflux esophagitis - Google Patents

Use of nizatidine to treat reflux esophagitis

Info

Publication number
CA2069162A1
CA2069162A1 CA002069162A CA2069162A CA2069162A1 CA 2069162 A1 CA2069162 A1 CA 2069162A1 CA 002069162 A CA002069162 A CA 002069162A CA 2069162 A CA2069162 A CA 2069162A CA 2069162 A1 CA2069162 A1 CA 2069162A1
Authority
CA
Canada
Prior art keywords
nizatidine
heartburn
reflux esophagitis
placebo
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002069162A
Other languages
English (en)
French (fr)
Inventor
Michelle L. Cloud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2069162A1 publication Critical patent/CA2069162A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002069162A 1991-05-28 1992-05-21 Use of nizatidine to treat reflux esophagitis Abandoned CA2069162A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70614591A 1991-05-28 1991-05-28
US07/706,145 1991-05-28

Publications (1)

Publication Number Publication Date
CA2069162A1 true CA2069162A1 (en) 1992-11-29

Family

ID=24836392

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002069162A Abandoned CA2069162A1 (en) 1991-05-28 1992-05-21 Use of nizatidine to treat reflux esophagitis

Country Status (10)

Country Link
EP (1) EP0516345A1 (enExample)
JP (1) JPH05148142A (enExample)
KR (1) KR920021144A (enExample)
AU (1) AU1721892A (enExample)
CA (1) CA2069162A1 (enExample)
HU (1) HU9201751D0 (enExample)
MX (1) MX9202507A (enExample)
NO (1) NO922019L (enExample)
TW (1) TW202387B (enExample)
ZA (1) ZA923711B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
WO2006047493A2 (en) 2004-10-21 2006-05-04 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
DK3354276T3 (da) * 2007-11-13 2020-03-30 Meritage Pharma Inc Sammensætninger til behandlingen af gastrointestinal inflammation
SG10201407965XA (en) 2009-12-02 2015-02-27 Aptalis Pharma Ltd Fexofenadine microcapsules and compositions containing them

Also Published As

Publication number Publication date
NO922019L (no) 1992-11-30
JPH05148142A (ja) 1993-06-15
NO922019D0 (no) 1992-05-22
AU1721892A (en) 1992-12-03
TW202387B (enExample) 1993-03-21
EP0516345A1 (en) 1992-12-02
MX9202507A (es) 1992-11-01
KR920021144A (ko) 1992-12-18
ZA923711B (en) 1993-11-22
HU9201751D0 (en) 1992-08-28

Similar Documents

Publication Publication Date Title
Lam et al. Treatment of duodenal ulcer with antacid and sulpiride: a double-blind controlled study
US5854267A (en) Method for preventing heartburn
Graham et al. Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis
US5204118A (en) Pharmaceutical compositions and methods for treating the symptoms of overindulgence
RU2159614C2 (ru) Высушенные замораживанием композиции ондансетрона и способ лечения млекопитающих
US5989588A (en) Methods and compositions for preventing and treating heartburn
Kang et al. Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer: comparison of initial healing and recurrence after healing
Agrawal et al. Healing of benign gastric ulcer: a placebo-controlled comparison of two dosage regimens of misoprostol, a synthetic analog of prostaglandin E1
Carroccio et al. Domperidone plus magnesium hydroxide and aluminum hydroxide: a valid therapy in children with gastroesophageal reflux: a double-blind randomized study versus placebo
Tytgat et al. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis: a review of three large, double-blind, controlled trials
Cloud et al. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study.
EP0516345A1 (en) Use of nizatidine for the manufacture of a medicament for the treatment of reflux esophagitis
Gunasekaran et al. Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability
Dolby et al. A trial of cromoglycic acid in recurrent aphthous ulceration
Armbrecht et al. Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole—comparison of 24‐hour intragastric and oesophageal pH
Navert Treatment of gastric ulcer with enprostil
Farup Compliance with anti‐ulcer medication during short‐term healing phase clinical trials
Morris et al. Antacids and peptic ulcer--a reappraisal.
Hendel et al. Morning or evening dosage of omeprazole for gastro‐oesophageal reflux disease?
Hui et al. Maintenance therapy for duodenal ulcer: a randomized controlled comparison of seven forms of treatment
US5667794A (en) Heartburn treatment
Barrow et al. The use of purified veratrum viride alkaloids in the treatment of essential hypertension
JP2001509791A (ja) 胃腸障害の治療用組成物及び方法
Lam et al. Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer
EP1019066B1 (en) Methods and compositions for preventing and treating heartburn

Legal Events

Date Code Title Description
FZDE Discontinued